Clinical trials: Arthritis, Psoriatic (PsA)
Psoriatic Arthritis (PsA)
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body.
- Trial name
- NCT07111494
- Testing
- GLP-1 agonists, Nutrition Counseling
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Medical College of Wisconsin
Psoriatic Arthritis
Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)
This will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and…
- Trial name
- PsOWell (NCT05631223)
- Testing
- Telemedicine
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- University of Pennsylvania
Ankylosing Spondylitis, Psoriatic Arthritis
Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium
This observational study will document to what extent in daily clinical practice the work productivity is affected before and after the start of adalimumab treatment.
- Trial name
- SPACTIVE (NCT01845818)
- Volunteers
- 183 people
- Sponsor
- AbbVie
Psoriatic Arthritis
A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis
The purpose of this study is to learn about the safety and effects of the study medicine for the potential treatment of Psoriatic Arthritis (PsA).
- Trial name
- NCT05195814
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Pfizer
Psoriatic Arthritis
Initial Treatment With Golimumab in Early PsA
The investigators will perform a 22-week randomized, double-blind, placebo-controlled trial of golimumab + methotrexate (MTX) versus methotrexate alone in methotrexate-naïve patients with Psoriatic Arthritis (PsA).
- Trial name
- NCT01871649
- Testing
- golimumab, methotrexate
- Where
- 2 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Psoriatic Arthritis
Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis
Title Safety and Efficacy of Tofacitinib vs Methotrexate in the treatment of Psoriatic Arthritis- An Open Label Randomized single center study Psoriatic arthritis is defined as an inflammatory arthropathy associated with skin…
- Trial name
- PsOLSET-BD (NCT03736161)
- Testing
- Group A- Tofacitinib, Group B- Methotrexate
- Where
- Bangladesh
- Volunteers
- 61 people
- Sponsor
- Globe Pharmaceuticals Limited
Psoriatic Arthritis
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3…
- Trial name
- INVIGORATE 2 (NCT04209205)
- Testing
- AIN457 6 mg/kg i.v., AIN457 3 mg/kg
- Where
- 80 sites in United States, Brazil and 13 more
- Volunteers
- 381 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Arthritis
A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis
The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as…
- Trial name
- STRIDE-PsA (NCT07417995)
- Testing
- Biologic or targeted synthetic DMARD (b/tsDMARD)
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- Royal United Hospitals Bath NHS Foundation Trust
PsA (Psoriatic Arthritis)
Effect of Metformin on Carotid Atherosclerosis for Non-diabetic Patients With PsA (CAMPA Study)
Background: Psoriatic arthritis (PsA) is a common chronic inflammatory disease with a prevalence up to 670 every 100,000 subjects.
- Trial name
- NCT05988684
- Testing
- Metformin
- Where
- Hong Kong
- Volunteers
- 24 people
- Sponsor
- Chinese University of Hong Kong
Autoimmune Diseases, Rheumatoid Arthritis (RA)
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in…
- Conditions
- Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO)
- Trial name
- NCT07455578
- Testing
- S-4321
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Seismic Therapeutic AU Pty Ltd
Spondyloarthritis (SpA), Psoriatic Arthritis (PsA)
Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity
The aim of the present work is to assess the nutritional status among different rheumatic diseases patients and to study its association with the corresponding diseases activity.
- Conditions
- Spondyloarthritis (SpA), Psoriatic Arthritis (PsA), Systemic Lupus Erythematous (SLE), Systemic Sclerosis (SSc)
- Trial name
- NCT07277491
- Where
- Egypt
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Cairo University
Psoriatic Arthritis, Spondyloarthritis
The Corrona Psoriatic Arthritis and Spondyloarthritis (PsA-SpA) Registry
This prospective, non-interventional, research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for PsA-SpA in a cohort of patients cared for by rheumatologists across…
- Trial name
- NCT02530268
- Volunteers
- 5,000 people
- Sponsor
- CorEvitas
Psoriatic Arthritis
National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study
The purpose of this study is to determine whether DC-STAMP, a protein on the surface of osteoclast precursors (OCPs), can be used as a biologic marker in Psoriatic Arthritis (PsA).
- Trial name
- NCT01123265
- Testing
- Methotrexate, Anti-TNF
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Rochester
Psoriatic Arthritis
REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)
The overall objective of the study was to describe the long-term effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting.
- Trial name
- NCT00127842
- Testing
- Etanercept
- Volunteers
- 110 people
- Sponsor
- Amgen
Psoriatic Arthritis
DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA
The Investigators will examine if DC-STAMP can serve as an early marker of TNFi response in PsA. Identification of such a biomarker would permit rapid transition to a new agent, a major treatment advance.
- Trial name
- NCT03011242
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNFα-IR)…
- Trial name
- BE COMPLETE (NCT03896581)
- Testing
- Bimekizumab
- Where
- 92 sites in United States, Australia and 9 more
- Volunteers
- 400 people
- Sponsor
- UCB Biopharma SRL
Psoriatic Arthritis
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in participants with Active Psoriatic Arthritis (PsA).
- Trial name
- NCT02319759
- Testing
- Guselkumab, Ustekinumab
- Where
- 41 sites in United States, Canada and 5 more
- Volunteers
- 149 people
- Sponsor
- Janssen Research & Development, LLC
Autoimmune Diseases, Inflammatory Bowel Diseases
Chronic Inflammatory Disease, Lifestyle and Treatment Response
Chronic inflammatory diseases (CID) - including inflammatory bowel diseases (Crohn's disease and ulcerative colitis), rheumatic conditions (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis), inflammatory skin…
- Conditions
- Autoimmune Diseases, Inflammatory Bowel Diseases, Crohn Disease (CD), Colitis, Ulcerative (UC)
- Trial name
- BELIEVE (NCT03173144)
- Testing
- Primary exposure variable, Other (exploratory) exposure variables
- Where
- 3 sites in Denmark
- Volunteers
- 233 people
- Sponsor
- University of Southern Denmark
Psoriatic Arthritis
An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic, immune-mediated, systemic disease affecting less than 1% of people with variations by parts of the world, and around 20%-30% of participants with psoriasis.
- Trial name
- UPtimum-PsA (NCT05616871)
- Where
- 89 sites in France, Germany and 2 more
- Volunteers
- 464 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Psoriatic Arthritis Study of Izokibep
Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA). This study will evaluate the efficacy of izokibep in subjects with PsA.
- Trial name
- NCT05623345
- Testing
- Izokibep
- Where
- 71 sites in United States, Bulgaria and 6 more
- Volunteers
- 351 people
- Sponsor
- ACELYRIN Inc.